Zheng L, Zhang FJ. Adult rhabdomyosarcoma combined with acute myeloid leukemia: A case report. World J Clin Cases 2024; 12(3): 582-586 [PMID: 38322472 DOI: 10.12998/wjcc.v12.i3.582]
Corresponding Author of This Article
Fen-Juan Zhang, MD, Nurse, Department of Hematology, Lishui Municipal Central Hospital, No. 289 Kuocang Road, Lishui 323000, Zhejiang Province, China. zhangfenjuan84@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 26, 2024; 12(3): 582-586 Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.582
Adult rhabdomyosarcoma combined with acute myeloid leukemia: A case report
Lu Zheng, Fen-Juan Zhang
Lu Zheng, Fen-Juan Zhang, Department of Hematology, Lishui Municipal Central Hospital, Lishui 323000, Zhejiang Province, China
Author contributions: Zheng L designed the report and wrote the paper; Zhang FJ revised the paper; all the authors have read and approved the final version of this manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fen-Juan Zhang, MD, Nurse, Department of Hematology, Lishui Municipal Central Hospital, No. 289 Kuocang Road, Lishui 323000, Zhejiang Province, China. zhangfenjuan84@163.com
Received: September 19, 2023 Peer-review started: September 19, 2023 First decision: December 5, 2023 Revised: December 17, 2023 Accepted: January 4, 2024 Article in press: January 4, 2024 Published online: January 26, 2024 Processing time: 118 Days and 19 Hours
Abstract
BACKGROUND
Rhabdomyosarcoma is a tumor of mesenchymal origin. Secondary leukemia is a complication of previous transformation to other hematologic disorders or is a treatment-related acute myeloid leukemia secondary to cytotoxic chemotherapy or radiation therapy for other malignancies.
CASE SUMMARY
We present the case of a 36-year-old female patient who was diagnosed with rhabdomyosarcoma and acute myeloid leukemia. Further disease progression was observed after multiline chemotherapy. Eventually, the patient suffered cerebral hemorrhage, which resulted in death.
CONCLUSION
The incidence of rhabdomyosarcoma in adults is extremely low, and secondary leukemia caused by rhabdomyosarcoma is even rarer. Secondary leukemia has a very poor prognosis and a low overall survival rate.
Core Tip: This article reports on a patient with rhabdomyosarcoma who developed acute myeloid leukemia (AML-M5a) after 11 chemotherapy sessions. Eventually, the patient suffered cerebral hemorrhage, which resulted in death. The incidence of rhabdomyosarcoma in adults is extremely low, and secondary leukemia caused by rhabdomyosarcoma is even rarer. Secondary leukemia has a very poor prognosis and a low overall survival rate.
